Semuloparin, as opposed to the commonly used enoxaparin, decreased the risk of clotting and death by 25 percent during the study.
In addition to using Semuloparin as a drug for patients recovering from orthopedic surgery, semuloparin may also be helpful in oncology preventative care.
The results of the study were presented at the 21st International Congress of Thrombosis in Milan, Italy.
Read the McMaster University release on semuloparin.
Read Becker’s Orthopedic & Spine Review coverage on post surgery care:
-Domestic Evolving Spine Care Systems: A Model for the Rest of the World? Q & A with Chris Zorn of Spine Surgical Innovation
-Orthofix Announces Three Sports Medicine Products
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
